625PDPembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study. (23rd October 2018) - Ueno, M; Chung, H C; Nagrial, A; Marabelle, A; Kelley, R K; Xu, L; Mahoney, J; Pruitt, S K; Oh, D-Y